Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 1 recruiting now early-phase tilt small index

Human Parainfluenza Virus Type 3: early-phase trial registry

1 of 1 indexed Human Parainfluenza Virus Type 3 trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #11,370 of 28,707 conditions by registered trial count.

1 US clinical trials · 1 currently recruiting · #11,370 of 28,707 conditions by registered trial count

Human Parainfluenza Virus Type 3: 1 US clinical trial tracked, 1 recruiting.

Human Parainfluenza Virus Type 3 is the subject of 1 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is National Institute of Allergy and Infectious Diseases (NIAID), running 1 of these trials.

Enrollment posture brief

Registry condition human-parainfluenza-virus-type-3

OPEN 1 | RECR 100% | LATE 0 | EARLY 1 | RANK #11370 | SPON 1

Nearest open-share peer: Aortic Arch Aneurysm (100% recruiting · 5 trials)

Human Parainfluenza Viru (th…100%Ablation80%ACL Reconstruction80%Abuse, Drug60%Acceptability60%
Open-enrollment share among volume-matched conditions near Human Parainfluenza Virus Type 3

Human Parainfluenza Virus Type 3 lists 1 open slots (100% of 1 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Human Parainfluenza Virus Type 3 on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Human Parainfluenza Virus Type 3 is recruiting above its size-band peers.

    1 of 1 indexed trials (100%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

Phase 11

Phase Distribution

PhaseTrial count
Phase 1 1

Named interventions

Most-linked intervention names on Human Parainfluenza Virus Type 3 records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

B/HPIV3/HMPV-F-B365 vaccine Biological
1 trials
B/HPIV3/HMPV-PreF-A vaccine Biological
1 trials
Placebo Drug
1 trials

US sites by state

Facility locations filed on Human Parainfluenza Virus Type 3 trials. A trial with sites in several states counts in each.

Tennessee 1 trials
New York 1 trials
Maryland 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Human Parainfluenza Virus Type 3 page

1 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Human Parainfluenza Virus Type 3 condition card totals 1 registered trials; most-linked intervention B/HPIV3/HMPV-F-B365 vaccine; top US site state Tennessee. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.